Practical management of Chronic Myeloid Leukemia in Belgium

peer reviewed ; Imatinib has drastically changed the outcome of patients with chronic myeloid leukemia (CML), with the majority of them showing a normal life span. Recently, the development of second and third generation tyrosine kinase inhibitors (TKIs) and the possibility of treatment discontinuation made the management of these patients more challenging. In this review, practical management guidelines of CML are presented, adapted to the Belgian situation in 2014. In first line chronic phase patients, imatinib, nilotinib and dasatinib can be prescribed. While second generation TKIs give fas... Mehr ...

Verfasser: Benghiat, FS.
Beguin, Yves
Dessars, B.
Devos, T.
Lewalle, P.
Mineur, P.
Straetmans, N.
Van Eygen, K.
Verhoef, G.
Knoops, L.
Dokumenttyp: journal article
Erscheinungsdatum: 2015
Verlag/Hrsg.: Ariez Medical Publishing
Schlagwörter: Chronic Myeloid Leukemia / Imatinib / Nilotinib / Dasatinib / Bosutinib / Ponatinib / response / therapy / drug interactions / adverse events / Human health sciences / Hematology / Sciences de la santé humaine / Hématologie
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-26592010
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : https://orbi.uliege.be/handle/2268/172675